Top 5 Drug Type | Count |
---|---|
Small molecule drug | 18 |
Prophylactic vaccine | 2 |
CAR-T | 1 |
Synthetic peptide | 1 |
Chemical drugs | 1 |
Target |
Mechanism CB antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date25 Jun 2018 |
Target |
Mechanism TGF-β1 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism TGF-β1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date22 Dec 2024 |
Sponsor / Collaborator |
Start Date01 Dec 2024 |
Sponsor / Collaborator |
Start Date22 Nov 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Fluorofenidone ( TGF-β1 x p38γ ) | Fibrosis, Liver More | Phase 2 |
Mefunidone Hydrochloride ( TGF-β1 ) | Type 2 diabetes mellitus with established diabetic nephropathy More | Phase 2 |
Zeta55 ( HDAC6 ) | Prostatic Cancer More | Preclinical |
EEF2K inhibitors(Central South University) ( EEF2K ) | Triple Negative Breast Cancer More | Preclinical |
Uric acid inhibitors compound1b(Central South University) ( Uric acid ) | Hyperuricemia More | Preclinical |